(Q45109095)

9 December 2017

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis (English)

1 reference

9 December 2017

1 reference

D A Sica

1

1 reference

9 December 2017

M R Marino

2

1 reference

9 December 2017

J L Hammett

3

1 reference

9 December 2017

I Ferreira

4

1 reference

9 December 2017

T W Gehr

5

1 reference

9 December 2017

N F Ford

6

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Clinical Pharmacology & Therapeutics

9 December 2017

1 reference

9 December 2017

62

1 reference

9 December 2017

6

1 reference

9 December 2017

610-618

1 reference

Renal disease and drug metabolism: an overview

9 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Goals of antihypertensive treatment and planning of therapeutic trials.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

ACE inhibitors in renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Metabolism of drugs by the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Principles of drug administration in renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

Dose-response relationships following oral administration of DuP 753 to normal humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990080-1

10.1016/S0009-9236(97)90080-1

7 January 2021

Identifiers

DOI

1 reference

9 December 2017

1 reference